Sygnature Discovery Unveils £1 Million Chemistry Facility Upgrade
Sygnature Discovery, an integrated drug discovery contract research organisation (CRO), has completed a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment.
Sygnature Discovery has doubled the synthesis and purification capacity of its high-throughput chemistry (HTC) platform, now delivering twice the output. The upgrade includes the integration of supercritical fluid chromatography (SFC), making both SFC and reverse-phase purification available. Combined with Sygnature's high-throughput screening (HTS) capabilities, the enhanced HTC platform enables faster compound production and screening, supporting accelerated drug candidate identification.
The upgraded facilities will be fully operational from August and mark a significant milestone in Sygnature’s ongoing growth strategy.
Geraint Jones, Director of Chemistry at Sygnature Discovery, commented: “Our successful track record over the past 20 years on client projects demonstrates our ability to validate robust syntheses and utilize automated processes to deliver high-quality science quickly and efficiently.”
“This investment in our capabilities further enhances the value for our customers and reinforces our commitment to delivering cutting-edge services. Our customers want to partner with a CRO that will help them hit their milestones. This expansion proves we are that partner. We have the facilities, flexibility, and scientific excellence to deliver.”
